PharmaEssentia Dirección
Dirección controles de criterios 3/4
El CEO de PharmaEssentia es Ko-Chung Lin, nombrado en Jan 2017, tiene una permanencia de 7.83 años. posee directamente un 1.73% de las acciones de la empresa, con un valor de NT$3.56B. La antigüedad media del equipo directivo y de la junta directiva es de 5.1 años y 3.3 años, respectivamente.
Información clave
Ko-Chung Lin
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 7.8yrs |
| Participación del CEO | 1.7% |
| Permanencia media de la dirección | 5.1yrs |
| Promedio de permanencia en la Junta Directiva | 3.3yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings
Aug 20
PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues
Jul 02PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues
Jul 02Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?
Apr 02Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term
Mar 18PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 06Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade
Mar 04PharmaEssentia (GTSM:6446) Is Using Debt Safely
Feb 10What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jan 06
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | NT$1b |
| Mar 31 2024 | n/a | n/a | NT$442m |
| Dec 31 2023 | n/a | n/a | -NT$624m |
| Sep 30 2023 | n/a | n/a | -NT$890m |
| Jun 30 2023 | n/a | n/a | -NT$1b |
| Mar 31 2023 | n/a | n/a | -NT$2b |
| Dec 31 2022 | n/a | n/a | -NT$1b |
| Sep 30 2022 | n/a | n/a | -NT$2b |
| Jun 30 2022 | n/a | n/a | -NT$2b |
| Mar 31 2022 | n/a | n/a | -NT$3b |
| Dec 31 2021 | NT$9m | NT$9m | -NT$3b |
| Sep 30 2021 | n/a | n/a | -NT$3b |
| Jun 30 2021 | n/a | n/a | -NT$3b |
| Mar 31 2021 | n/a | n/a | -NT$2b |
| Dec 31 2020 | NT$9m | NT$9m | -NT$2b |
| Sep 30 2020 | n/a | n/a | -NT$1b |
| Jun 30 2020 | n/a | n/a | -NT$862m |
| Mar 31 2020 | n/a | n/a | -NT$856m |
| Dec 31 2019 | NT$9m | NT$8m | -NT$843m |
Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Ko-Chung es razonable en comparación con empresas de tamaño similar en el mercado TW.
Compensación vs. Ingresos: La compensación de Ko-Chung ha sido consistente con los resultados de la empresa en el último año.
CEO
Ko-Chung Lin
7.8yrs
Permanencia
NT$9,389,000
Compensación
Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & Chief Pharmaceutical Officer | 12.2yrs | NT$8.49m | 1.05% NT$ 2.2b | |
| Founder | 7.8yrs | NT$9.39m | 1.73% NT$ 3.6b | |
| President | no data | NT$8.49m | 0.61% NT$ 1.2b | |
| Accounting Manager & Senior Manager of Finance | 9.1yrs | sin datos | sin datos | |
| VP and Head of Business Operations & Strategy | 2.8yrs | sin datos | sin datos | |
| Chief Scientific Officer | 2.3yrs | sin datos | 0.010% NT$ 21.0m | |
| VP and Head of Corporate Communications & Advocacy | 2.8yrs | sin datos | sin datos | |
| Senior VP and Head of Sales & Marketing | 3.8yrs | sin datos | sin datos | |
| Senior VP & Head of People | 2.8yrs | sin datos | sin datos | |
| Chief Medical Officer | 7.8yrs | sin datos | 0.0061% NT$ 12.5m | |
| Head of Japan Medical Affairs | 6.3yrs | sin datos | sin datos | |
| Chief Operating Officer of Taichung Plant | 6.3yrs | sin datos | sin datos |
5.1yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de 6446 es experimentado (5.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman & Chief Pharmaceutical Officer | 12.2yrs | NT$8.49m | 1.05% NT$ 2.2b | |
| Founder | 3.3yrs | NT$9.39m | 1.73% NT$ 3.6b | |
| President | 9.5yrs | NT$8.49m | 0.61% NT$ 1.2b | |
| Independent Director | less than a year | sin datos | sin datos | |
| Independent Director | less than a year | sin datos | 0.13% NT$ 260.5m | |
| Independent Director | 10.7yrs | NT$120.00k | 0.029% NT$ 59.1m | |
| Independent Director | 6.4yrs | NT$120.00k | 0.00060% NT$ 1.2m | |
| Independent Director | less than a year | sin datos | 0.0012% NT$ 2.5m | |
| Chairperson of Japan | 3.5yrs | sin datos | sin datos | |
| Director | 3.3yrs | NT$95.00k | 0.24% NT$ 502.1m | |
| Director | less than a year | sin datos | sin datos | |
| Director | less than a year | sin datos | sin datos |
3.3yrs
Permanencia media
Junta con experiencia: La junta directiva de 6446 se considera experimentada (3.3 años de antigüedad promedio).